

Astellas Clinical Transparency

Information Regarding Results Posting for a Transitioned Trial

EudraCT ID: 2022-002860-59

EU CTID: 2024-515185-13-00

Protocol Title: An Open-label Extension (OLE) Phase 3 Trial to Assess the Safety of Intravitreal Administration of avacincaptad pegol (Complement C5 Inhibitor) in Patients with Geographic Atrophy Who Previously Completed Phase 3 Study ISEE2008 (GATHER2)

Sponsor: Astellas Pharma Global Development, Inc.

The results for this trial are posted on Clinical Trials Information System (CTIS), as the trial has officially transitioned to this platform.